Developed using the company’s HIFI technology platform, the early screening product can accurately detect six cancers that are highly prevalent in China.
They include liver, colorectal, oesophagal, pancreatic, gastric and lung cancer.
The product has demonstrated an 82% traceability accuracy, 99.09% specificity and 87.58% sensitivity.
The company stated that the self-iterative HIFI technology platform can help reduce product development and testing service costs, which in turn contributes to the effort to make early multi-cancer screening more affordable.
Berry Oncology’s new one-time precision product is claimed to be the first of its kind in the world to be developed using whole-genome sequencing (WGS) of cell-free DNA (cfDNA).
The technology has the capability to capture early cancer signals in a broader range.
This helps to reduce missed detections, which are caused by differences in individual and molecular biological characteristics across several types of tumours.
Berry Oncology CEO Zhou Jun said: “Since its establishment, Berry Oncology has been dedicated to developing technologies and delivering products for early cancer screening based on the spectrum of malignant tumours, to help more high-risk people identify hidden risks and help more patients prolong survival time and improve quality of life.
“Moving forward, Berry Oncology will continue to optimise its technology system and iterate early screening products to deliver more advanced early cancer screening solutions in accordance with the actual market demand and environment.
“In the meanwhile, we will further our partnerships with industry players, universities and research organisations to co-build an ecosystem for cancer prevention and treatment that enables innovations more accessible.”